中国实用儿科杂志2026，Vol.41Issue(2)：125-128,4.DOI:10.19538/j.ek2026020608
儿童中重度特应性皮炎系统治疗进展
Advances in systemic treatment for pediatric moderate-to-severe atopic dermatitis
落娜 1张岚 1肖汀1
作者信息
- 1. 中国医科大学附属第一医院,辽宁沈阳 110001
- 折叠
摘要
Abstract
Atopic dermatitis(AD)is a chronic,recurrent,pruritic,type 2 inflammatory skin disease that commonly affects children.AD is primarily characterized by eczematous skin lesions,intense itching and elevated serum IgE levels,and is often associated with food allergy,asthma and allergic rhinitis.Pediatric cases of mild AD are often controlled by topical corticosteroids and/or calcineurin inhibitors.However,pediatric patients with moderate-to-severe AD usually require systemic therapies.Currently,first-line systemic treatments for moderate-to-severe AD include biologics,cyclosporine and corticosteroids,while second-line treatment mainly consists of JAK inhibitors and other traditional immunosuppressants.This article focuses on the latest advances in the systemic pharmacological therapies.关键词
特应性皮炎/生物制剂/儿童/JAK抑制剂Key words
atopic dermatitis/biologics/child/JAK inhibitors分类
医药卫生引用本文复制引用
落娜,张岚,肖汀..儿童中重度特应性皮炎系统治疗进展[J].中国实用儿科杂志,2026,41(2):125-128,4.
